Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021. The patent number is EP3341754. This reinforces the first patent grant which was in the USA back in January 2020. The company has further patents pending in key large countries which have high numbers of radiotherapy cancer treatment centres.
on PATENTSCOP
on Espacenet
Related Posts
Dr. Shakardokht Jafari named 2024 Innovator of the Year at Dynamic Awards in Brighton's Grand Hotel.
This order is for a number of DOSEmapper™ devices and for our DOSEmapper™ Bead Reading Service.
Dr. Shakar Jafari discusses Women in Innovation and cancer care on Huffington Post.
TrueInvivo enhances cancer care with accurate, high-resolution in-vivo dosimetry system, optimizing radiotherapy outcomes.
